Solid tumor
Conditions
Interventions
Sponsors
Yantai affiliated Hospital of Binzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18~70 years old; 2.All participants must have a clear pathological diagnosis, confirmed by histopathological examination of gastroscopy, bronchoscopic sampling, and/or surgical resection specimens; 3.Patients in stage II to IV; 4.ECOG PS:0-2; 5.Estimated survival >=6 months; 6.Before the first dose of study drug, the laboratory test value meets the following conditions: (1) Blood routine (no blood transfusion within 14 days before screening, no correction with hematopoietic stimulating factor drugs): white blood cell (WBC) >=3.0 × 10^9/L; absolute neutrophil count (ANC) >=1.5 × 10^9/L; platelet (PLT) = 100 × 109/L; hemoglobin (HGB) >=9.0 g/dL; (2) Liver function: aspartate transferase (AST) =50 mL/minute (using the Cockcroft/Gault formula); (4) Coagulation function: international normalized ratio (INR) 1.5 x ULN without clinical or imaging confirmation of pancreatitis, it can be enrolled); Amylase 1.5 x ULN without clinical or radiographic confirmation of pancreatitis can be enrolled); alkaline phosphatase (ALP) <=2.5 ULN; 7. All patients must fully understand the content of the study, be willing and able to provide informed consent, and actively participate in all aspects of the study, including follow-up visits.
Exclusion criteria
Exclusion criteria: (1) Patients with uncontrolled heart disease, diabetes, hypertension, lung disease and other chronic diseases, or with active infection (such as tuberculosis, HIV, HBV, HCV infection). Patients with concomitant autoimmune diseases requiring systemic immunosuppressant or hormone therapy; (2) Known presence of brain metastases or spinal cord compression; (3) patients who are undergoing other clinical trials or interventions; (4) Severe mental illness or cognitive impairment, unable to understand the research content or cooperate with the completion of the necessary research process; (5) Allergy to gp96 antigen-peptide complex; (7) The patient voluntarily withdrew from the experiment; (8) Pregnant or lactating women; (9) Other patients who are considered by the treating physician to be unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Control Rate (DCR); | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor marker changes;Quality of life assessment; | — |
Countries
China
Contacts
Public ContactSixiang Lin
Yantai affiliated Hospital of Binzhou Medical University
Outcome results
None listed